Researchers have found in a new systematic review and meta-analysis that higher levels of environmental pollutants and ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

Connect Biopharma (CNTB) announced that the Company’s collaborator and exclusive licensee in China, Simcere Pharmaceutical, has submitted its New Drug Application, or NDA, for rademikibart to the ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in ...

New data reveals sponsors risk wasting billions by designing overly complex trials and repeatedly recruiting from oversaturated investigator sites Boston, US. 9 July, 2025. Dr. Gen Li, CEO of Phesi, a ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...